Selank vs Semax
Mechanisms, Evidence, and the Difference That Matters
Developed by related Russian research programs, Selank and Semax are often grouped together. Their research profiles, however, point in different directions.
Selank and Semax are related synthetic peptides, but they are not interchangeable.
What the Brain-Imaging Study Actually Shows
A 2020 study used resting-state fMRI to examine Selank, Semax, and placebo in 52 healthy participants. The researchers focused on connectivity involving the amygdala and the dorsolateral prefrontal cortex—regions associated with anxiety and executive function.
The study supports the narrower conclusion that the compounds did not produce identical short-term connectivity effects. It does not prove that Selank simply “quiets” the brain or that Semax broadly “activates” it, and it does not establish a clinical benefit for healthy adults.
What Human Research Exists?
Selank: Generalized Anxiety Disorder
The best-known human evidence for Selank is a 2008 Russian comparative study involving 62 people with generalized anxiety disorder or neurasthenia. Selank was compared with benzodiazepine treatment, and the paper reported anxiety improvement without the same sedating profile. The study is small, comes from one research environment, and has not been widely replicated outside Russia.
A separate 2008 study reported changes in immune signaling among people with anxiety-related disorders who received Selank. That is an interesting signal, but it does not establish Selank as a general immune treatment.
Zozulya AA, Neznamov GG, Seredenin SB, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48. PMID: 18454096Semax: Stroke Recovery and Cognitive Stress
Semax's clearer human evidence is in people recovering from ischemic stroke. A 2018 Russian study followed 110 patients during rehabilitation and reported higher plasma BDNF levels and improved functional-recovery measures in groups receiving Semax. This is clinically relevant evidence, but it concerns stroke rehabilitation—not routine use by healthy people seeking better focus.
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of Semax in patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3 Pt 2):61-68. PMID: 29798983Evidence Boundary
Both compounds have legitimate research behind them. The problem is that online summaries often turn limited evidence into broad promises. The distinctions below keep the comparison grounded.
| Question | Evidence Level | Bottom Line |
|---|---|---|
| Does Selank have human anxiety research? | LIMITED HUMAN | Yes. A small Russian comparative study reported benefit, but independent replication is limited. |
| Does Semax have human stroke-rehabilitation research? | LIMITED HUMAN | Yes. Russian studies report recovery-related benefits, including a 110-patient rehabilitation study. |
| Are the detailed mechanisms fully established in people? | MOSTLY PRECLINICAL | No. Many GABA, neurotrophin, dopamine, serotonin, and immune-pathway claims come from animal or laboratory research. |
| Are either proven cognitive enhancers for healthy adults? | NOT ESTABLISHED | No. Neither has a strong, independently replicated clinical evidence base for that purpose. |
What the Research Profiles Suggest
Neither compound has enough high-quality human evidence to predict how a particular person will respond. The research does, however, give each one a different overall profile.
The Selank Profile
Selank is the more anxiety- and stress-oriented compound in the published literature. Proposed mechanisms include effects on GABA-related signaling, enkephalin breakdown, and immune signaling. The important limitation is that much of the mechanism work is preclinical and the human studies are small.
The Semax Profile
Semax is the more neuroprotection- and recovery-oriented compound in the published literature. Proposed mechanisms include effects on neurotrophin signaling and cellular responses to neurological injury. Its most relevant human evidence comes from stroke rehabilitation, which should not be treated as proof of everyday cognitive enhancement.
Intranasal vs Subcutaneous
Protokol X Route Finding
Based on the available literature, intranasal is the most research-aligned probable route for both Selank and Semax. It is the route most closely reflected in the published work that established these compounds, including the human Selank anxiety literature and intranasal Semax research.
Subcutaneous injection is widely discussed in peptide communities, but it does not have a comparable human evidence base for these two compounds. We did not find a strong head-to-head human trial showing that subcutaneous injection provides better absorption, stronger effects, or better clinical outcomes than intranasal administration.
That distinction matters: intranasal should be described as the better-supported research route, not as a route proven superior for every person. Product formulation, nasal delivery, compound identity, and individual health factors can all affect the result.
Route assessment based on the published administration route in the Selank human literature and intranasal Semax research. Direct intranasal-versus-subcutaneous human comparisons for these compounds remain lacking.If the question is which route best matches the existing research, intranasal is the stronger answer. If the question is whether intranasal has been conclusively proven better than subcutaneous injection, the evidence does not yet support that claim.
What About Combining Them?
Online discussions often describe the pair as “calm focus”: Selank for the calmer profile and Semax for the more activating profile. That idea is easy to understand, but it is not supported by meaningful combined human trials.
The 2020 fMRI study examined the compounds as separate conditions; it did not establish the benefit or safety of taking them together. Claims about an established Selank–Semax stack therefore go beyond the published human evidence.
Protokol X Assessment
Selank has the more calming, anxiety-oriented research profile. Semax has the more activating, neuroprotection-oriented research profile. That is the clearest useful distinction between them.
Both compounds have legitimate research foundations, but the human evidence is limited, geographically concentrated, and tied to specific clinical settings. Neither has strong evidence as a general cognitive enhancer for healthy adults, and neither is FDA-approved.
The practical takeaway is not that one is universally better. It is that they have been studied for different questions: Selank more often for anxiety and stress regulation, Semax more often for neuroprotection and stroke rehabilitation. Online claims frequently extend well beyond those evidence boundaries.